tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
IgG Deficiency D017099 1 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Polymyositis D017285 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Arm Injuries D001134 1 associated lipids
Intussusception D007443 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Kumai Y et al. Reversible Cerebral Vasoconstriction Syndrome After Heart Transplantation: A Case Report. 2017 Transplant. Proc. pmid:29198694
Ricordi C et al. Donor bone marrow cell infusion without recipient cytoablation induces acceptance of rat islet allografts. 1994 Transplant. Proc. pmid:7527967
Tsugita M et al. Hepatocytes or liver nonparenchymal cells plus FK 506 prolong liver xenograft survival. 1994 Transplant. Proc. pmid:7527969
Kobayashi M et al. Production of monoclonal antibody against recombinant human FKBP-12 and subcellular localization of FKBP-12 in human mononuclear and polymorphonuclear cells. 1993 Transplant. Proc. pmid:7679832
Kuroki H et al. Effect of FK 506 and donor-specific blood transfusion on the rat composite tissue limb allograft and the mechanism of long-term graft survival. 1993 Transplant. Proc. pmid:7679833
Machida M et al. Effect of temperature and hematocrit on plasma concentration of FK 506. 1991 Transplant. Proc. pmid:1721266
Nakajima H and Oka T The inhibition of T-cell-receptor-induced Fas ligand upregulation by cyclosporine and FK 506. 1996 Transplant. Proc. pmid:8623224
Ko S et al. Different immunosuppressive effects of liposomal FK506 in liver and kidney transplantation. 1996 Transplant. Proc. pmid:8623229
McDiarmid S et al. One hundred children treated with tacrolimus after primary orthotopic liver transplantation. 1998 Transplant. Proc. pmid:9636564
Toda F et al. Non-heart-beating donor kidney transplantation under tacrolimus immunosuppression. 2000 Transplant. Proc. pmid:11119909
Videla CO Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy. 2009 Jul-Aug Transplant. Proc. pmid:19715995
Ohara K et al. Toxicologic evaluation of FK 506. 1990 Transplant. Proc. pmid:1689910
Mazali FC et al. Posttransplant diabetes mellitus: incidence and risk factors. 2008 Transplant. Proc. pmid:18455010
Stratta RJ et al. FK 506 induction and rescue therapy in pancreas transplant recipients. 1996 Transplant. Proc. pmid:8623492
O'Neill EA et al. The FK 506-sensitive nature of the interleukin-2 promoter is derived from a specific array of multiple regulatory elements. 1991 Transplant. Proc. pmid:1721298
Birk PE et al. Preliminary experience with FK 506 in pediatric renal transplant recipients: a single-center report. 1996 Transplant. Proc. pmid:8623493
Watanabe K et al. Donor bone marrow cell infusion is effective in inducing tolerance in dogs treated with fractionated lymphoid irradiation and FK506. 2000 Transplant. Proc. pmid:11120286
Nelson PA et al. Effect of immunosuppressive drugs on cytokine gene transcription studied by message amplification phenotyping (MAPPing) polymerase chain reaction. 1991 Transplant. Proc. pmid:1721299
Schulz T et al. Tacrolimus/mycophenolate mofetil/steroid-based immunosuppression after pancreas-kidney transplantation with single shot antithymocyte globulin. 1998 Transplant. Proc. pmid:9636623
Ciancio G et al. Use of intravenous tacrolimus to reverse vascular rejection in kidney and simultaneous kidney-pancreas transplantation. 1998 Transplant. Proc. pmid:9636624
Perrella A et al. Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience. 2010 Transplant. Proc. pmid:20534267
Watanabe Y et al. The expression of nonmuscle myosin heavy chain in rat renal transplantation. 1999 Transplant. Proc. pmid:10578260
Meçule A et al. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. 2010 Transplant. Proc. pmid:20534290
Alloway R et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. 2005 Transplant. Proc. pmid:15848559
Tellis V et al. No-load sirolimus with tacrolimus and steroids is safe and effective in renal transplantation. 2005 Transplant. Proc. pmid:15848571
Chen JS et al. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus. 2009 Transplant. Proc. pmid:19545678
Akbas SH et al. Evaluation of the new EMIT tacrolimus assay in kidney and liver transplant recipients. 2004 Jan-Feb Transplant. Proc. pmid:15013308
Bakar F et al. Low-density lipoprotein oxidizability and the alteration of its fatty acid content in renal transplant recipients treated with cyclosporine/tacrolimus. 2009 Transplant. Proc. pmid:19545695
Cabello M et al. Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. 2010 Transplant. Proc. pmid:20970603
Morris RE et al. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. 1990 Transplant. Proc. pmid:1697111
Marcén R et al. Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation. 2010 Transplant. Proc. pmid:20970609
Woo J et al. Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. 1990 Transplant. Proc. pmid:1697112
Wynn C et al. High level of TGF-beta in organ transplantation might be due to rejection rather than calcineurin inhibitor medication. 2002 Transplant. Proc. pmid:12176408
Alessiani M et al. Total orthotopic small bowel transplantation in swine under FK 506. 1994 Transplant. Proc. pmid:7518148
Date K et al. Effect of FK 506 on graft survival in rat small intestinal allografts. 1992 Transplant. Proc. pmid:1376516
Murase N et al. Bone marrow augmentation for heart, liver, and small bowel transplantation: prolongation of graft survival and incidence of graft-versus-host disease. 1995 Transplant. Proc. pmid:7533386
Ishibashi M et al. Effect of FK 506 on generation of activated macrophages invading rejected skin allografts in rats: discrepancy of in vitro versus in vivo effects. 1991 Transplant. Proc. pmid:1721330
Mitsuoka N et al. Cytokinic character of graft infiltrate versus peripheral blood lymphocytes during calcineurin inhibitor-resistant small bowel transplantation in rats. 2003 Transplant. Proc. pmid:12591532
Charco R et al. CD28 regulation in liver transplant recipients treated with two different immunosuppressive regimens. 1999 Transplant. Proc. pmid:10616508
Hoshinaga K et al. Regimen of tacrolimus-based immunosuppression with basiliximab, mycophenolate mofetil, and low-dose steroid reduces acute rejection in kidney transplants. 2005 Transplant. Proc. pmid:15919457
Yoshimura N et al. Safety analysis after tacrolimus immunosuppression in renal transplant recipients in Japan: 5-year results in >1500 patients. 2005 Transplant. Proc. pmid:15919458
Signorell J et al. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient. 2010 Transplant. Proc. pmid:21094874
Hayes D et al. Aerosolized tacrolimus: a case report in a lung transplant recipient. 2010 Transplant. Proc. pmid:21094875
Hanafusa T et al. Long-term impact of hepatitis virus infection on kidney transplant recipients and a pilot study of the effects of interferon alpha on chronic hepatitis C. 1995 Transplant. Proc. pmid:7533440
Yagihashi A et al. HLA matching effect in liver transplantation. 1992 Transplant. Proc. pmid:1281569
Shapiro R et al. FK 506 in clinical kidney transplantation. 1991 Transplant. Proc. pmid:1721361
Todo S et al. One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. 1991 Transplant. Proc. pmid:1703340
McCauley J et al. Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome. 1991 Transplant. Proc. pmid:1721362
Zeevi A et al. Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. 1991 Transplant. Proc. pmid:1703341
Weis M et al. Impact of immunosuppression on coronary endothelial function after cardiac transplantation. 1998 Transplant. Proc. pmid:9595131
Urbizu JM et al. Safety and efficacy of tacrolimus rescue therapy in 55 kidney transplant patients treated with cyclosporine. 2003 Transplant. Proc. pmid:12962765
Zucker K et al. Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy. 1997 Feb-Mar Transplant. Proc. pmid:9123027
Ronchetti F et al. Mucosal hyaluronic acid quantification in small bowel transplantation in pigs. 1996 Transplant. Proc. pmid:8907950
Montagnino G et al. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in kidney transplantation: twelve-month follow-up. 2002 Transplant. Proc. pmid:12176515
Zmonarski S et al. Expression of PBMC TLR4 in Renal Graft Recipients Who Experienced Delayed Graft Function Reflects Dynamic Balance Between Blood and Tissue Compartments and Helps Select a Problematic Patient. Transplant. Proc. pmid:30056893
Terakura M et al. Effects of peritransplant administration of hematopoietic growth factors on the development of chronic allograft rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083380
Song Z et al. FK 506 prevents islet xenograft rejection: a study in the pig-to-rat model. 1999 Feb-Mar Transplant. Proc. pmid:10083437
Inagaki K et al. Effects of FK506 and 15-deoxyspergualin in rat orthotopic liver transplantation. 1989 Transplant. Proc. pmid:2468210
Scantlebury V et al. New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. 1991 Transplant. Proc. pmid:1721395
Lee S et al. Mycophenolic acid trough level measurements and clinical outcomes in kidney transplantation recipients on a fixed dose (1.5 g/d) of mycophenolate mofetil in Korea. 2010 Transplant. Proc. pmid:20430174
Kim JM et al. Preemptive therapy in adult liver transplant recipients in CMV-endemic area. 2010 Transplant. Proc. pmid:20430182
Ali IH et al. Incidence and risk factors for post-renal transplant diabetes mellitus. 2011 Transplant. Proc. pmid:21440763
Hariharan S et al. Long-term renal and pancreas function with tacrolimus rescue therapy following kidney/pancreas transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123462
McGrath JS and Shehata M Chronic allograft nephropathy: prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution. 2001 Transplant. Proc. pmid:11377500
Stratta RJ Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multi-center report. The FK/MMF Multi-Center Study Group. 1997 Feb-Mar Transplant. Proc. pmid:9123463
Baid S et al. Tacrolimus-associated posttransplant diabetes mellitus in renal transplant recipients: role of hepatitis C infection. 2002 Transplant. Proc. pmid:12176569
Kelly JS and Sharkey J Immunosuppressants-ligands as neuroprotectants. 2001 Transplant. Proc. pmid:11377506
Jonas S et al. Posttransplant malignancy and newer immunosuppressive protocols after liver transplantation. 1996 Transplant. Proc. pmid:8962257
Akioka K et al. Diabetes in renal transplant recipients treated with tacrolimus. 2002 Transplant. Proc. pmid:12176570
Mohacsi P et al. Immunosuppression in ABO-incompatible transplantation. 2001 Transplant. Proc. pmid:11377508
Cai W et al. Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients. 2018 Transplant. Proc. pmid:29735215
Kauffman HM et al. Drug regimens affect cadaveric kidney graft survival. 2001 Feb-Mar Transplant. Proc. pmid:11267176
Zhang J et al. Chemotherapy for De Novo Gastric Adenocarcinoma After Deceased Orthotopic Liver Transplantation: A Case Report. Transplant. Proc. pmid:28104131
Langrehr JM et al. Indefinite small bowel allograft survival after limited immunosuppressive therapy is not due to specific hyporesponsiveness. 1991 Transplant. Proc. pmid:1721425
Zou XM et al. Immunosuppressive effect of FK506 on orthotopic liver and small bowel xenotransplantation (xenoOLTx and SBTx). 1996 Transplant. Proc. pmid:8658729
Honbo T et al. The oral dosage form of FK-506. 1987 Transplant. Proc. pmid:2445068
Ettenger RB New immunosuppressive agents in pediatric renal transplantation. 1998 Transplant. Proc. pmid:9723350
Eun SC et al. Prolongation of the rat composite tissue allograft survival by the combination of tolerogenic immature dendritic cells and short-term treatment with FK506. 2013 Transplant. Proc. pmid:23769045
Liu W et al. Transfusion of endothelial cells with lentivirus-mediated expression of fas ligand prolonged survival of rat liver allograft. 2012 Transplant. Proc. pmid:22664023
Jain A et al. Almost total absence of chronic rejection in primary pediatric liver transplantation under tacrolimus. 2002 Transplant. Proc. pmid:12176649
Matevossian E et al. Nitric oxide inhibition and consecutive Aspisol application show a prolonged survival of orthotopic transplanted livers in a rat model. 2008 Transplant. Proc. pmid:18555092
Groetzner J et al. Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up? 2001 Feb-Mar Transplant. Proc. pmid:11267373
Kupferman JC et al. Activation of the renal renin-angiotensin system by cyclosporine A and FK 506 in the rat. 1994 Transplant. Proc. pmid:7524224
van den Berg AP et al. Recurrent HCV infection reduces the requirement for tacrolimus after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267375
Kattner A et al. Conversion from CyA to CyA-NOF in a cholestatic liver grafted patient with CyA malabsorption. 1994 Transplant. Proc. pmid:7524225
Mochizuki M et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis. 1991 Transplant. Proc. pmid:1721456
Chávez R et al. Hepatotrophic effect of cyclosporine and FK 506 is not mimicked by rapamycin. 1999 Transplant. Proc. pmid:10500655
Roat MI et al. Treatment of Cogan's syndrome with FK 506: a case report. 1991 Transplant. Proc. pmid:1721457
Escartín A et al. Orthotopic small bowel transplantation in pigs without steroids. 1999 Transplant. Proc. pmid:10500720
Meiser BM et al. Continuous infusion of angiopeptin significantly reduces accelerated graft vessel disease induced by FK 506 in a rat heart allograft model. 1992 Transplant. Proc. pmid:1384201
Ochiai T et al. Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. 1987 Transplant. Proc. pmid:2484094
Ginevri F et al. Expression of collagen by renal fibroblasts treated with FK 506 in vitro. 1998 Transplant. Proc. pmid:9636387
Hutchinson IV et al. Differences in the mode of action of cyclosporine and FK 506. 1998 Transplant. Proc. pmid:9636388
Iwata H et al. Prolongation of xenograft survival by combining donor-specific intravenous presensitization with FK 506. 2002 Transplant. Proc. pmid:12431592
Itagaki F et al. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. 2002 Transplant. Proc. pmid:12431607
Zhang J et al. Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients. 2010 Transplant. Proc. pmid:21094797
Guleria S et al. Tacrolimus (Pan Graf) as de novo therapy in renal transplant recipients in India. 2006 Transplant. Proc. pmid:16979989
Teng D et al. Comparison of rapamycin versus FK506 on expression of cytoprotective genes in the rat kidney allografts undergoing chronic allograft nephropathy. 2006 Transplant. Proc. pmid:16980034
Takaya S et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. 1991 Transplant. Proc. pmid:1703691
Budde K et al. Tacrolimus rescue therapy in late rejection after renal transplantation: outcome after 18 months. 1998 Transplant. Proc. pmid:9636503